Article

  • Article

    To Spend Less on Healthcare, Invest in More Medicines
    04.05.2022

    Read John Stanford and JF Formela's op-ed on how we can lower health costs by spending more on drugs.

  • Article

    CMS’s Devastating Blow to Seniors
    02.09.2022

    Read Incubate Advisory Council member Gaurav Gupta's op-ed on the CMS's decision to cover Alzheimer's drugs.

  • Article

    Investors Say Drug-Pricing Measure May Shift Incentives for Biotech Venture Funding
    12.02.2021

    A drug-pricing bill the House passed in November could affect which life-sciences startups venture-capital investors are likely to back.

  • Article

    House passage of Build Back Better gets mixed reaction
    11.22.2021

    As investors in biotechnology and pharmaceuticals, we're alarmed by the potential consequences of the drug-pricing measure included in the Build Back Better Act, which just passed the House.

  • Article

    Regeneron, Janssen Drugs Fit Profile Targeted in Spending Bill
    11.10.2021

    Plan would negotiate prices of expensive older pharmaceuticals Moderate Democrats sought compromise to preserve innovation

  • Article

    Drug pricing bill’s unintended consequences will distort drug development
    11.09.2021

    The ultimate victims of all the unintended consequences of the current proposal will be all of us as future patients.

  • Article

    Leading Venture Capital Group Concerned with Prescription Drug Deal
    11.04.2021

    Investors in biotechnology and pharmaceuticals aere concerned about the potential consequences of the new drug-pricing legislation before Congress in the Build Back Better Act.

  • Article

    Cost of Care: Rare diseases expose need to revamp US drug pricing policy
    10.20.2021

    Developing more effective treatments for patients with no other options while also keeping costs down will require a balancing act with no clear solution

  • Article

    Democrats’ Drug Price Controls Threaten Biotech Research, Patients
    09.21.2021

    Biotech investors sounded alarms at the National Press Club last week about what they would mean. They said the price-control scheme would dry up investor interest in the biotech sector.

  • Article

    VC Daily: Venture Capitalists Push Back Against Drug-Pricing Bill
    09.16.2021

    If price controls are enacted on drugs, investment will no longer flow to innovative new biotech treatments

  • Article

    Venture firms warn R&D funding for new drugs will ‘drop off a cliff’ if Dem bill approved
    09.16.2021

    Democrats move forward with giving Medicare the power to negotiate drug prices for certain drugs and extend those prices to commercial plans.

  • Article

    Cost of Care: Biotech VCs fret over ‘thumb on the scale’ Medicare reform plans
    09.15.2021

    For venture capitalists investing in companies at the earliest stages of scientific discovery and drug development, the ramifications of pricing control could change the landscape in ways that vastly undermine future funding decisions